Press Releases Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Market Closed - Xetra Other stock markets 11:36:02 2024-06-11 am EDT			After market 12:38:26 pm
8.98 ^EUR	-1.32%		9.03	+0.56%

Apr. 05	Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	MT
Mar. 28	Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management	Jun. 04	EQ
DD: APONTIS PHARMA AG: Thomas Milz, buy	May. 14	EQ
DD: APONTIS PHARMA AG: be executive GmbH, buy	May. 14	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	May. 13	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	May. 13	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	May. 13	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	May. 13	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	May. 13	EQ
Apontis Pharma : Earnings Call Q1/24 Presentation	May. 08	PU
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed	May. 08	EQ
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	Apr. 05	EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	Apr. 05	EQ
APONTIS PHARMA expects profitable growth again in 2024	Mar. 28	EQ
Apontis Pharma : Earnings Call 2023 Presentation	Mar. 27	PU
APONTIS PHARMA successfully completes performance and efficiency improvement program	Feb. 06	EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	Nov. 09	EQ
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program	Nov. 08	EQ
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline	23-08-10	EQ
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024	23-07-31	EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched	23-07-27	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Press Releases

Filters